IN2013DE01960A - - Google Patents

Info

Publication number
IN2013DE01960A
IN2013DE01960A IN1960DE2013A IN2013DE01960A IN 2013DE01960 A IN2013DE01960 A IN 2013DE01960A IN 1960DE2013 A IN1960DE2013 A IN 1960DE2013A IN 2013DE01960 A IN2013DE01960 A IN 2013DE01960A
Authority
IN
India
Prior art keywords
chikungunya virus
seq
rnai agents
inhibition
nspl
Prior art date
Application number
Inventor
Parashar Deepti
A Arankalle Vidya
S Paingankar Mandar
Kumar Satyendra
D Gokhale Mangesh
B Sudeep A
S Shinde Sapna
Original Assignee
Indian Council Of Medical Res Icmr
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Indian Council Of Medical Res Icmr filed Critical Indian Council Of Medical Res Icmr
Priority to AU2014285701A priority Critical patent/AU2014285701C1/en
Priority to IN1960DE2013 priority patent/IN2013DE01960A/en
Priority to CN201480037556.6A priority patent/CN105392886B/en
Priority to PCT/IN2014/000441 priority patent/WO2015001570A1/en
Priority to US14/899,135 priority patent/US9574195B2/en
Priority to EP14753163.6A priority patent/EP3017046B1/en
Publication of IN2013DE01960A publication Critical patent/IN2013DE01960A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention relates to RNAi agents for inhibition of Chikungunya virus are described herein. The present invention provides RNAi agents for inhibition of Chikungunya virus, particularly by targeting the E2 gene and nsPl gene or both of the Chikungunya virus; the RNAi agents comprising of the entire nucleotide sequence set forth is SEQ ID 1 or SEQ ID 5 or combination thereof; or comprising of 15 or more contiguous nucleotides as set forth is SEQ ID 1 or SEQ ID 5 or combination thereof along with the addition nucleotides from the contiguous region of the E2 and nsPl target gene. The invention further provides a RNAi composition for reducing the E2 protein and nsPl protein level of Chikungunya virus and inhibition of Chikungunya virus replication. The combination of RNAi agents provides an excellent therapeutic composition for treatment of Chikungunya virus infection.
IN1960DE2013 2013-07-02 2014-07-02 IN2013DE01960A (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
AU2014285701A AU2014285701C1 (en) 2013-07-02 2014-07-02 RNAi agent for inhibition of Chikungunya virus
IN1960DE2013 IN2013DE01960A (en) 2013-07-02 2014-07-02
CN201480037556.6A CN105392886B (en) 2013-07-02 2014-07-02 For inhibiting to cut the RNAi agent of elder brother's tribute subviral
PCT/IN2014/000441 WO2015001570A1 (en) 2013-07-02 2014-07-02 Rnai agent for inhibition of chikungunya virus
US14/899,135 US9574195B2 (en) 2013-07-02 2014-07-02 RNAi agent for inhibition of Chikungunya virus
EP14753163.6A EP3017046B1 (en) 2013-07-02 2014-07-02 Rnai agent for inhibition of chikungunya virus

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN1960DE2013 IN2013DE01960A (en) 2013-07-02 2014-07-02

Publications (1)

Publication Number Publication Date
IN2013DE01960A true IN2013DE01960A (en) 2015-06-26

Family

ID=51383914

Family Applications (1)

Application Number Title Priority Date Filing Date
IN1960DE2013 IN2013DE01960A (en) 2013-07-02 2014-07-02

Country Status (6)

Country Link
US (1) US9574195B2 (en)
EP (1) EP3017046B1 (en)
CN (1) CN105392886B (en)
AU (1) AU2014285701C1 (en)
IN (1) IN2013DE01960A (en)
WO (1) WO2015001570A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20200024793A (en) * 2017-07-06 2020-03-09 애로우헤드 파마슈티컬스 인코포레이티드 RNAi Agents and Methods of Inhibiting the Expression of Alpha-ENaC

Also Published As

Publication number Publication date
US20160145621A1 (en) 2016-05-26
AU2014285701A1 (en) 2016-01-21
EP3017046A1 (en) 2016-05-11
CN105392886B (en) 2019-10-22
EP3017046B1 (en) 2019-09-11
WO2015001570A1 (en) 2015-01-08
CN105392886A (en) 2016-03-09
AU2014285701C1 (en) 2021-07-15
AU2014285701B2 (en) 2021-04-01
US9574195B2 (en) 2017-02-21

Similar Documents

Publication Publication Date Title
CY1124327T1 (en) MODIFICATION OF HEPATITIS B VIRUS (HBV) EXPRESSION
MX2020011805A (en) RNAi AGENTS FOR HEPATITIS B VIRUS INFECTION.
PH12015501953A1 (en) Substituted nucleotide analogs
EA201790420A1 (en) MEANS PRESENTING A MODIFIED TWO-STEAM RNA
PH12015501423A1 (en) Substituted nucleosides, nucleotides and analogs thereof
PH12016500660A1 (en) Substituted nucleosides, nucleotides and analogs thereof
EA201791417A1 (en) Gentingin-induced gene expression induced by rnc-interferon
EA201190178A1 (en) REPLACED NUCLEOSIDE AND NUCLEOTIC ANALOGUES
PH12015502018A1 (en) 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh
EA025278B9 (en) Antiviral composition against dna or rna enveloped or non-enveloped viruses
EA202191537A1 (en) COMPOSITIONS AND METHODS FOR INHIBITION OF HEPATITIS B VIRUS GENE EXPRESSION
NZ630800A (en) Methods of preparing substituted nucleotide analogs
MX2021006745A (en) CHEMICALLY-MODIFIED RNAi CONSTRUCTS AND USES THEREOF.
EA201990628A1 (en) 2'-SUBSTITUTED-N6-SUBSTITUTED PURINE NUCLEOTIDES FOR THE TREATMENT OF DISEASES CAUSED BY RNA-VIRUS
MX2016008518A (en) Artificial match-type mirna for controlling gene expression and use therefor.
MX354676B (en) Benzofuran compounds for the treatment of hepatitis c virus infections.
MX2013003698A (en) Prophylactic or therapeutic agent for fibrosis.
IL274363B2 (en) Use of specific sirna against protein s for the treatment of hemophilia
IN2013DE01960A (en)
UA114603C2 (en) P0 gene silencing constructs and use
UA117563C2 (en) Composition for treating cancer associated with hpv infection
WO2020104649A3 (en) Novel rna compositions and methods for inhibiting angptl8
MX2015013036A (en) Promoter compositions.
MX2022001864A (en) Rnai constructs for inhibiting slc30a8 expression and methods of use thereof.
MX2020002110A (en) Compositions and methods for detecting and treating insulin resistance.